Answers are grounded in this paper and cite their sources.
Conflicting evidence exists on the contribution of multiple glycemic markers towards the risk of chronic kidney disease (CKD). The aim of this study was to evaluate the associations between different glucose parameters and risk of CKD. PubMed, EMBASE, and Web of Science were searched from inception through July 2025. Fixed-effects or random-effects model was used to calculate the pooled risk estimates for the associations of glycemic markers (including glycated hemoglobin [HbA 1c ], fasting blood glucose [FBG], 2-hour oral glucose tolerance test [2hOGTT], and homeostatic model assessment of insulin resistance [HOMA-IR]) with the incidence and/or progression of CKD, as well as end-stage renal disease (ESRD) incidence. Dose-response associations were assessed by using generalized least-squares trend estimation. The search yielded 66 cohort studies involving 1,890,077 participants, with 90,551 cases of incident CKD, 4,246 cases of CKD progression, and 12,741 cases of incident ESRD. Participants with a higher level of HbA 1c were significantly associated with a 43% increased risk of CKD incidence (relative risk [RR]: 1.43, 95% confidence interval [CI]: 1.24–1.66). The risk of incident CKD also increased among individuals with elevated levels of FBG (RR: 1.40, 95% CI: 1.24–1.60), 2hOGTT (RR: 1.35, 95% CI: 1.16–1.57), and HOMA-IR (RR: 1.57, 95% CI: 1.34–1.83). Similar findings were observed for CKD progression and ESRD incidence, with RR ranging from 1.16 (95% CI: 1.04–1.61) to 1.82 (95% CI: 1.07–3.07). The dose-response analyses showed nonlinear associations of HbA 1c and FBG with CKD incidence, with the risk remaining relatively flat at lower levels and then increasing above 6.5% and 6.3 mmol/L, respectively. The association between HbA 1c and ESRD also showed a potential nonlinear pattern, with the risk increasing above 7.0%. Higher levels of glycemic markers were consistently associated with an increased risk of incidence and progression of CKD, as well as ESRD incidence. These results support the notion that glycemic management may be an effective strategy for both primary and secondary prevention of CKD, especially in individuals with abnormal glucose metabolism. Not applicable.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: